HomeCompareQPTFF vs MRK

QPTFF vs MRK: Dividend Comparison 2026

QPTFF yields 6578.95% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 QPTFF wins by $903160944306728.13M in total portfolio value
10 years
QPTFF
QPTFF
● Live price
6578.95%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$903160944306728.13M
Annual income
$876,939,829,008,324,100,000.00
Full QPTFF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — QPTFF vs MRK

📍 QPTFF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodQPTFFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, QPTFF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
QPTFF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

QPTFF
Annual income on $10K today (after 15% tax)
$559,210.53/yr
After 10yr DRIP, annual income (after tax)
$745,398,854,657,075,400,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, QPTFF beats the other by $745,398,854,657,075,400,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of QPTFF + MRK for your $10,000?

QPTFF: 50%MRK: 50%
100% MRK50/50100% QPTFF
Portfolio after 10yr
$451580472153364.06M
Annual income
$438,469,914,504,162,050,000.00/yr
Blended yield
97.10%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

QPTFF
No analyst data
Altman Z
2.1
Piotroski
1/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

QPTFF buys
0
MRK buys
0
No recent congressional trades found for QPTFF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricQPTFFMRK
Forward yield6578.95%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$903160944306728.13M$56.8K
Annual income after 10y$876,939,829,008,324,100,000.00$9,798.13
Total dividends collected$901400901751488.63M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: QPTFF vs MRK ($10,000, DRIP)

YearQPTFF PortfolioQPTFF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$668,595$657,894.74$11,206$366.19+$657.4KQPTFF
2$41,824,271$41,108,874.62$12,650$502.35+$41.81MQPTFF
3$2,448,103,158$2,403,351,188.44$14,407$694.19+$2448.09MQPTFF
4$134,091,931,604$131,472,461,224.39$16,585$967.82+$134091.92MQPTFF
5$6,873,616,037,527$6,730,137,670,710.89$19,342$1,363.89+$6873616.02MQPTFF
6$329,775,376,912,396$322,420,607,752,241.75$22,913$1,947.19+$329775376.89MQPTFF
7$14,809,652,943,541,940$14,456,793,290,245,678.00$27,662$2,823.89+$14809652943.51MQPTFF
8$622,603,404,175,321,200$606,757,075,525,731,300.00$34,159$4,173.35+$622603404175.29MQPTFF
9$24,505,715,232,153,338,000$23,839,529,589,685,744,000.00$43,337$6,308.80+$24505715232153.29MQPTFF
10$903,160,944,306,728,100,000$876,939,829,008,324,100,000.00$56,776$9,798.13+$903160944306728.13MQPTFF

QPTFF vs MRK: Complete Analysis 2026

QPTFFStock

Quest PharmaTech Inc., a pharmaceutical company, develops antibody based immunotherapeutic products for cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, an anti-CA-125 antibody, which has completed Phase II clinical trial for the treatment of ovarian cancer. In addition, it develops, manufactures, and commercializes immunotherapy products for pancreatic cancer. Further, the company develops products by using proprietary transdermal delivery technologies for dermatology and wound healing applications; skin penetrating active molecules for cosmetic and pharmaceutical use; and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class. Quest PharmaTech Inc. is headquartered in Edmonton, Canada.

Full QPTFF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this QPTFF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

QPTFF vs SCHDQPTFF vs JEPIQPTFF vs OQPTFF vs KOQPTFF vs MAINQPTFF vs JNJQPTFF vs ABBVQPTFF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.